NCT03488667View on ClinicalTrials.gov

Perioperative mFOLFOX Plus Pembrolizumab in Gastroesophageal Junction (GEJ) and Stomach Adenocarcinoma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

June 27, 2018

Primary Completion Date

April 30, 2024

Study Completion Date

April 30, 2025

Conditions
Gastro Esophageal Junction CancerStomach CancerAdenocarcinoma
Interventions
DRUG

Neoadjuvant Treatment - mFOLFOX6 & Pembrolizumab

Pembrolizumab, mFOLFOX Chemotherapy

DRUG

Adjuvant Treatment - mFOLFOX & Pembrolizumab

Pembrolizumab, mFOLFOX Chemotherapy

Trial Locations (1)

66205

The University of Kansas Cancer Center, Westwood

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

University of Kansas Medical Center

OTHER